WallStSmart

Intercontinental Exchange Inc (ICE)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 3012% more annual revenue ($309.06B vs $9.93B). ICE leads profitability with a 33.4% profit margin vs 33.1%. ICE appears more attractively valued with a PEG of 2.20. ICE earns a higher WallStSmart Score of 63/100 (C+).

ICE

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 7.5Value: 10.0Quality: 6.0
Piotroski: 6/9Altman Z: 0.60

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ICEUndervalued (+38.6%)

Margin of Safety

+38.6%

Fair Value

$255.26

Current Price

$156.83

$98.43 discount

UndervaluedFair: $255.26Overvalued
NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICE5 strengths · Avg: 9.0/10
Profit MarginProfitability
33.4%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
49.6%10/10

Strong operational efficiency at 49.6%

Market CapQuality
$88.85B9/10

Large-cap with strong market position

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Free Cash FlowQuality
$1.11B8/10

Generating 1.1B in free cash flow

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

Areas to Watch

ICE3 concerns · Avg: 3.3/10
PEG RatioValuation
2.204/10

Expensive relative to growth rate

P/E RatioValuation
27.0x4/10

Moderate valuation

Altman Z-ScoreHealth
0.602/10

Distress zone — elevated risk

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : ICE

The strongest argument for ICE centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 33.4% and operating margin at 49.6%.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bear Case : ICE

The primary concerns for ICE are PEG Ratio, P/E Ratio, Altman Z-Score.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

ICE profiles as a mature stock while NVO is a declining play — different risk/reward profiles.

ICE carries more volatility with a beta of 1.05 — expect wider price swings.

ICE is growing revenue faster at 7.8% — sustainability is the question.

ICE generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

ICE scores higher overall (63/100 vs 55/100), backed by strong 33.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intercontinental Exchange Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

The Intercontinental Exchange (ICE) is an American Fortune 500 company formed in 2000 that operates global exchanges, clearing houses and provides mortgage technology, data and listing services. The company owns exchanges for financial and commodity markets, and operates regulated exchanges and marketplaces.

Visit Website →

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?